![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…
Hydreight Reports 34% Year-Over-Year Q1 Revenue Growth, Improvement in Bottom Line Results, and Delivers Strong Performance Across Verticals
“It was an outstanding quarter. We exceeded our Q1 projections with approximately…
Firstunion Launches Worlds First Puff-to-Heat Product, PTH MASTER, Ushering in a New Era of Heated Tobacco
Jakarta, Indonesia, May 30, 2025 (GLOBE NEWSWIRE) -- On May 30, 2025,…
Singapore Unveils Insights from World’s First Technical Testing of Real World Applications of GenAI
First Global AI Assurance Pilot brought global testing companies and GenAI deployers…
